Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Neonatology

Free Subscription Articles published in Eur Respir J Retrieve available abstracts of 44 articles: HTML format

Single Articles

December 2025
1. HALLE O, Graeber SY, Kontsendorn J, Kessemeier C, et al
   Reduction of systemic inflammation by elexacaftor/tezacaftor/ivacaftor correlates with lung function improvement in cystic fibrosis.
   Eur Respir J. 2025;66:2500150.
   PubMed     Abstract available
   
   
   October 2025
2. HIRANI D, Selle J, Wagde V, Klymenko O, et al
   Targeting IL6-Edn1-FoxO1 axis enables lung growth in mechanically ventilated newborn mice.
   Eur Respir J. 2025 Oct 9:2401580. doi: 10.1183/13993003.01580-2024.
   PubMed     Abstract available
   
   
   September 2025
3. LOUVRIER C, Soreze Y, Mesinele J, de Becdelievre A, et al
   De novo SRRM2 variants in neuroendocrine cell hyperplasia of infancy and persistent tachypnea of infancy.
   Eur Respir J. 2025 Sep 18:2500777. doi: 10.1183/13993003.00777-2025.
   PubMed     Abstract available
   
   
   August 2025
4. PLANT BJ, Einarsson GG, Deasy KF, Dahly D, et al
   Cystic Fibrosis Microbiome-directed Antibiotic Therapy Trial in Exacerbations Results Stratified (CFMATTERS): results of a multicentre randomised controlled trial.
   Eur Respir J. 2025;66:2402443.
   PubMed     Abstract available
   
   
   July 2025
5. MALL MA, Wainwright CE, Legg J, Chilvers M, et al
   Elexacaftor/tezacaftor/ivacaftor in children aged >/=6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study.
   Eur Respir J. 2025;66:2402435.
   PubMed     Abstract available
   
   
   June 2025
6. RATJEN F, Stanojevic S, Gunawardena T, Eckford PDW, et al
   Relationship between theratyping in nasal epithelial cells and clinical outcomes in people with cystic fibrosis.
   Eur Respir J. 2025;65:2401855.
   PubMed     Abstract available
   
   
   January 2025
7. MCEVOY CT, MacDonald KD, Shorey-Kendrick LE, Davies MH, et al
   Nasal CPAP increases alveolar number in a rhesus monkey model of moderate prematurity.
   Eur Respir J. 2025 Jan 16:2400727. doi: 10.1183/13993003.00727-2024.
   PubMed     Abstract available
   
   
   
8. DIMOPOULOS K, Constantine A
   Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease.
   Eur Respir J. 2025;65:2402022.
   PubMed    
   
   
   
9. FOUZAS S, Dimitriou G
   Respiratory oscillometry in neonates and small infants: has the time come?
   Eur Respir J. 2025;65:2402242.
   PubMed    
   
   
   
10. IVY D, Rosenzweig EB, Abman SH, Beghetti M, et al
    Reply to: Treat-and-repair: a simple but powerful term for a complex multimodal approach in patients with pulmonary arterial hypertension associated with congenital heart disease.
    Eur Respir J. 2025;65:2402127.
    PubMed    
    
    
    
11. WERTHAMMER JW, Gozal D
    The 10-year temporal evolution of respiratory support and associated outcomes in extremely premature infants: betting on a favourable forecast for the next decade.
    Eur Respir J. 2025;65:2402194.
    PubMed    
    
    
    
12. MOISEENKO A, Sinadinos A, Sergijenko A, Pineault K, et al
    Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy.
    Eur Respir J. 2025;65:2301683.
    PubMed     Abstract available
    
    
    November 2024
13. LOFBERG L, Abrahamsson T, Bjorklund LJ, Hellstrom Westas L, et al
    Respiratory support and bronchopulmonary dysplasia in infants born at 22-26 weeks gestation in Sweden, 2004-2007 and 2014-2016.
    Eur Respir J. 2024 Nov 7:2401203. doi: 10.1183/13993003.01203-2024.
    PubMed     Abstract available
    
    
    
14. LIN B, Gong J, Keenan K, Lin F, et al
    Genome-wide association study of susceptibility to Pseudomonas aeruginosa infection in cystic fibrosis.
    Eur Respir J. 2024;64:2400062.
    PubMed     Abstract available
    
    
    
15. CROMWELL EA, Ostrenga JS, Sanders DB, Morgan W, et al
    Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA.
    Eur Respir J. 2024;64:2401146.
    PubMed     Abstract available
    
    
    October 2024
16. WANG G, Hallberg J, Merid SK, Kumar A, et al
    Body mass index trajectories from birth to early adulthood and lung function development.
    Eur Respir J. 2024 Oct 28:2400298. doi: 10.1183/13993003.00298-2024.
    PubMed     Abstract available
    
    
    
17. URBANTAT RM, Mall MA
    How many functioning ciliated airway epithelial cells are necessary for effective mucociliary clearance?
    Eur Respir J. 2024;64:2401573.
    PubMed    
    
    
    
18. WATERS V, Ratjen F
    Reply to: Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past.
    Eur Respir J. 2024;64:2401577.
    PubMed    
    
    
    
19. WATERS V, Quon B, Ratjen F
    Reply to: Steroids in cystic fibrosis exacerbations: are we picking the right patients?
    Eur Respir J. 2024;64:2401713.
    PubMed    
    
    
    
20. LIU Y, He KZ, Xu JF
    Oral corticosteroids for cystic fibrosis pulmonary exacerbation: seeking the future in the past.
    Eur Respir J. 2024;64:2401049.
    PubMed    
    
    
    
21. BEINART D, Forrester DL, Ramakrishnan S
    Steroids in cystic fibrosis exacerbations: are we picking the right patients?
    Eur Respir J. 2024;64:2401225.
    PubMed    
    
    
    September 2024
22. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    PubMed     Abstract available
    
    
    
23. REIX P, Chassagnon G
    The younger, the better: lessons learned from real-world studies on CFTR modulators in young children.
    Eur Respir J. 2024;64:2401178.
    PubMed    
    
    
    
24. STAHL M, Dohna M, Graeber SY, Sommerburg O, et al
    Impact of elexacaftor/tezacaftor/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles.
    Eur Respir J. 2024;64:2400004.
    PubMed     Abstract available
    
    
    
25. CHASSAGNON G, Burgel PR
    Reply: Reversal of structural abnormalities with elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: the earlier you start, the better the outcome will be!
    Eur Respir J. 2024;64:2401247.
    PubMed    
    
    
    
26. MIDDLETON PG, Simmonds NJ
    Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2024;64:2400929.
    PubMed    
    
    
    August 2024
27. IVY D, Rosenzweig EB, Abman SH, Beghetti M, et al
    Embracing the challenges of neonatal and paediatric pulmonary hypertension.
    Eur Respir J. 2024 Aug 29:2401345. doi: 10.1183/13993003.01345-2024.
    PubMed     Abstract available
    
    
    
28. VARGHESE NP, Austin ED, Galambos C, Mullen MP, et al
    An Interdisciplinary Consensus Approach to Pulmonary Hypertension in Developmental Lung Disorders.
    Eur Respir J. 2024 Aug 15:2400639. doi: 10.1183/13993003.00639-2024.
    PubMed     Abstract available
    
    
    July 2024
29. ZANNIN E, Rigotti C, Schulzke SM, Sindelar R, et al
    Early respiratory system reactance predicts respiratory outcomes in preterm infants: a retrospective, multicentre study.
    Eur Respir J. 2024 Jul 26:2400246. doi: 10.1183/13993003.00246-2024.
    PubMed     Abstract available
    
    
    
30. AGARWAL S, Jat KR, Gupta S, Sankar J, et al
    Video-based direct observation physiotherapy in children with cystic fibrosis: a randomised controlled trial.
    Eur Respir J. 2024;64:2400826.
    PubMed    
    
    
    June 2024
31. GOSS CH, VanDevanter DR
    Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes.
    Eur Respir J. 2024;63:2400858.
    PubMed    
    
    
    
32. WATERS V, Shaw M, Perrem L, Quon BS, et al
    A randomised trial of oral prednisone for cystic fibrosis pulmonary exacerbation treatment.
    Eur Respir J. 2024;63:2302278.
    PubMed     Abstract available
    
    
    May 2024
33. CAVERLY LJ, Ross BD, Dickson RP
    From gut to lung and back again: early life microbiota in cystic fibrosis.
    Eur Respir J. 2024;63:2400595.
    PubMed    
    
    
    April 2024
34. FURSTOVA E, Drevinek P, Novotna S, Libik M, et al
    Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay.
    Eur Respir J. 2024;63:2400156.
    PubMed    
    
    
    March 2024
35. FRAYMAN KB, Macowan M, Caparros-Martin J, Ranganathan SC, et al
    The Longitudinal Microbial and Metabolic Landscape of infant Cystic Fibrosis: The gut-lung axis.
    Eur Respir J. 2024 Mar 14:2302290. doi: 10.1183/13993003.02290-2023.
    PubMed     Abstract available
    
    
    
36. MCKONE EF
    Socioeconomic disparities in European cystic fibrosis outcomes: time to close the gap.
    Eur Respir J. 2024;63:2400328.
    PubMed    
    
    
    
37. XU X, Li JD, Green TJ, Wilson L, et al
    Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis.
    Eur Respir J. 2024;63:2301512.
    PubMed     Abstract available
    
    
    
38. KEREM E, Orenti A, Adamoli A, Hatziagorou E, et al
    Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain.
    Eur Respir J. 2024;63:2301241.
    PubMed     Abstract available
    
    
    
39. WIELPUTZ MO, Mall MA
    Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.
    Eur Respir J. 2024;63:2400234.
    PubMed    
    
    
    
40. CAZIER P, Chassagnon G, Dhote T, Da Silva J, et al
    Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2024;63:2301794.
    PubMed     Abstract available
    
    
    February 2024
41. COHEN R, Shteinberg M
    Unravelling the "frequent exacerbator" phenotype in cystic fibrosis.
    Eur Respir J. 2024;63:2400068.
    PubMed    
    
    
    
42. HOUSTON CJ, Alkhatib A, Einarsson GG, Tunney MM, et al
    Diminished airway host innate response in people with cystic fibrosis who experience frequent pulmonary exacerbations.
    Eur Respir J. 2024;63:2301228.
    PubMed     Abstract available
    
    
    
43. DOONEY M, Saba T
    Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Eur Respir J. 2024;63:2301392.
    PubMed    
    
    
    
44. BURGEL PR
    Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
    Eur Respir J. 2024;63:2400233.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Neonatology is free of charge.